Cognition Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Cognition Therapeutics, Inc. (CGTX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $102.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-07
- Cognition Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $45.00K, a 0.00% change year-over-year.
- Cognition Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $57.00K, a 5.56% increase year-over-year.
- Cognition Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $47.00K, a 6.82% increase year-over-year.
- Cognition Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $46.00K, a 6.98% increase year-over-year.
- Cognition Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $192.00K, a 20.75% increase from fiscal 2024.
- Cognition Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $159.00K, a 1.92% increase from fiscal 2023.
- Cognition Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $156.00K, a 2.63% increase from fiscal 2022.
- Cognition Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $152.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $102.00K 10-Q · filed 2026-08-07 | $149.00K derived: sum of 3 quarters · filed 2026-08-07 | $195.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $57.00K 10-Q · filed 2026-05-08 | $104.00K derived: sum of 2 quarters · filed 2026-05-08 | $150.00K derived: sum of 3 quarters · filed 2026-05-08 | $195.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $93.00K derived: sum of 2 quarters · filed 2026-03-26 | $138.00K derived: sum of 3 quarters · filed 2026-08-07 | $192.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $91.00K derived: sum of 2 quarters · filed 2026-08-07 | $145.00K 10-Q · filed 2025-11-06 | $189.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $99.00K 10-Q · filed 2026-08-07 | $143.00K derived: sum of 3 quarters · filed 2026-08-07 | $186.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $54.00K 10-Q · filed 2026-05-08 | $98.00K derived: sum of 2 quarters · filed 2026-05-08 | $141.00K derived: sum of 3 quarters · filed 2026-05-08 | $182.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $87.00K derived: sum of 2 quarters · filed 2026-03-26 | $128.00K derived: sum of 3 quarters · filed 2026-03-26 | $159.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $84.00K derived: sum of 2 quarters · filed 2025-11-06 | $115.00K 10-Q · filed 2025-11-06 | $154.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $72.00K 10-Q · filed 2025-08-07 | $111.00K derived: sum of 3 quarters · filed 2025-08-07 | $151.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $31.00K 10-Q · filed 2025-05-07 | $70.00K derived: sum of 2 quarters · filed 2025-05-07 | $110.00K derived: sum of 3 quarters · filed 2025-05-07 | $148.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $79.00K derived: sum of 2 quarters · filed 2025-03-20 | $117.00K derived: sum of 3 quarters · filed 2025-03-20 | $156.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $78.00K derived: sum of 2 quarters · filed 2024-11-13 | $117.00K 10-Q · filed 2024-11-13 | $154.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $77.00K 10-Q · filed 2024-08-08 | $114.00K derived: sum of 3 quarters · filed 2024-08-08 | $152.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $39.00K 10-Q · filed 2024-05-07 | $76.00K derived: sum of 2 quarters · filed 2024-05-07 | $114.00K derived: sum of 3 quarters · filed 2024-05-07 | $153.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $75.00K derived: sum of 2 quarters · filed 2024-03-26 | $114.00K derived: sum of 3 quarters · filed 2024-03-26 | $152.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $77.00K derived: sum of 2 quarters · filed 2023-11-02 | $115.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $77.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $38.00K 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |